News Neurosterix emerges with $63m for neuroscience pipeline A brand new biotech – Neurosterix – has been formed to take forward neuroscience programmes that originated at Switzerland’s Addex Therapeutics, including a drug for schiz
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face